Table 1.
Baseline patient characteristics grouped by outcomes
| All (n = 2740) | Survivors (n = 2571) | Patients with outcomes (n = 169) | P-value | |
|---|---|---|---|---|
| Age, years | 58.5 ± 10.5 | 58.3 ± 10.5 | 62.2 ± 10.6 | < 0.001 |
| Male, n (%) | 2272 (82.9) | 2139 (83.2) | 133 (78.7) | 0.132 |
| BMI, kg/m2 | 26.3 ± 3.3 | 26.3 ± 3.3 | 25.8 ± 3.5 | 0.042 |
| Smoking, n (%) | 880 (32.1) | 826 (32.1) | 54 (32) | 0.962 |
| Prediabetes, n (%) | 999 (36.5) | 943 (36.7) | 56 (33.1) | 0.354 |
| Diabetes, n (%) | 1280 (46.7) | 1193 (46.4) | 87 (51.5) | 0.200 |
| Hypertension, n (%) | 1777 (64.9) | 1643 (63.9) | 134 (79.3) | < 0.001 |
| Dyslipidemia, n (%) | 2182 (79.6) | 2046 (79.6) | 136 (80.5) | 0.780 |
| HF, n (%) | 211 (7.7) | 185 (7.2) | 26 (15.4) | < 0.001 |
| LVEF, (%) | 59.9 ± 8.7 | 60.1 ± 8.5 | 57.3 ± 10.8 | < 0.001 |
| Prior MI, n (%) | 901 (32.9) | 836 (32.5) | 65 (38.5) | 0.111 |
| Prior stroke, n (%) | 350 (12.8) | 320 (12.4) | 30 (17.8) | 0.045 |
| Peripheral vascular disease, n (%) | 188 (6.9) | 173 (6.7) | 15 (8.9) | 0.285 |
| Prior revascularization, n (%) | 870 (31.8) | 810 (31.5) | 60 (35.5) | 0.280 |
| PCI | 822 (30.0) | 765 (29.8) | 57 (33.7) | 0.275 |
| CABG | 86 (3.1) | 78 (3) | 8 (4.7) | 0.220 |
| Renal dysfunction, n (%) | 129 (4.7) | 108 (4.2) | 21 (12.4) | < 0.001 |
| Unstable angina, n (%) | 1162 (42.4) | 1092 (42.5) | 70 (41.4) | 0.788 |
| AMI, n (%) | 233 (8.5) | 220 (8.6) | 13 (7.7) | 0.696 |
| Silent ischeamia, n (%) | 541 (19.7) | 501 (19.5) | 40 (23.7) | 0.186 |
| Laboratory tests | ||||
| Hemoglobin, g/L | 4.9 (4.5, 5.2) | 4.9 (4.5, 5.2) | 4.7 (4.4, 5.3) | 0.269 |
| Platelet, × 109/L | 0.4 (0.3, 0.5) | 0.4 (0.3, 0.5) | 0.4 (0.3, 0.5) | 0.902 |
| HbA1C, % | 6.5 ± 1.2 | 6.5 ± 1.2 | 6.6 ± 1.1 | 0.669 |
| FBG, mmol/L | 6.6 ± 2.4 | 6.6 ± 2.4 | 7.5 ± 3.0 | < 0.001 |
| TC, mmol/L | 3.8 (3.3, 4.6) | 3.8 (3.3, 4.6) | 3.9 (3.3, 4.6) | 0.75 |
| TG, mmol/L | 1.4 (1.0, 2.0) | 1.4 (1.0, 2.0) | 1.5 (1.2, 2.0) | 0.116 |
| LDL-C, mmol/L | 2.2 (1.8, 2.9) | 2.2 (1.8, 2.9) | 2.3 (1.8, 2.9) | 0.784 |
| HDL-C, mmol/L | 1.0 (0.9, 1.2) | 1.0 (0.9, 1.2) | 1.0 (0.8, 1.2) | 0.308 |
| eGFR, mL/min/1.73 m2 | 98.8 ± 26.2 | 99.3 ± 25.9 | 91.3 ± 29.9 | < 0.001 |
| Hs-CRP, mmol/L | 2.7 ± 3.2 | 2.7 ± 3.2 | 3.5 ± 3.6 | 0.005 |
| TyG index | 8.8 ± 0.8 | 8.8 ± 0.8 | 9.0 ± 0.7 | < 0.001 |
| SHR | 0.9 ± 0.2 | 0.8 ± 0.2 | 0.9 ± 0.3 | < 0.001 |
| Angiographic characteristics, n (%) | ||||
| Multivessel disease | 2395 (87.4) | 2238 (87) | 157 (92.9) | 0.026 |
| Ostial lesion | 440 (16.1) | 413 (16.1) | 27 (16) | 0.976 |
| Bifurcation | 944 (34.5) | 893 (34.7) | 51 (30.2) | 0.227 |
| Intervention treatment, n (%) | ||||
| LM | 37 (1.4) | 37 (1.4) | 0 (0.0) | 0.167 |
| LAD | 940 (34.3) | 889 (34.6) | 51 (30.2) | 0.243 |
| LCX | 377 (13.8) | 358 (13.9) | 19 (11.2) | 0.327 |
| RCA | 1367 (49.9) | 1273 (49.5) | 94 (55.6) | 0.124 |
| Graft | 7 (0.3) | 6 (0.2) | 1 (0.6) | 0.360 |
| Number of lesions ≥ 2 | 732 (26.7) | 689 (26.8) | 43 (25.4) | 0.700 |
| Number of stents ≥ 2 | 1546 (56.4) | 1470 (57.2) | 76 (45) | 0.002 |
| Procedural success | 2233 (81.5) | 2105 (81.9) | 128 (75.7) | 0.047 |
| Medication at discharge, n (%) | ||||
| DAPT | 2716 (99.1) | 2548 (99.1) | 168 (99.4) | 1.000 |
| Aspirin | 2740 (100.0) | 2571 (100) | 169 (100) | 1.000 |
| Clopidogrel | 2539 (92.7) | 2379 (92.5) | 160 (94.7) | 0.301 |
| Ticagrelor | 599 (21.9) | 570 (22.2) | 29 (17.2) | 0.127 |
| β-blockers | 2509 (91.6) | 2358 (91.7) | 151 (89.3) | 0.284 |
| Statin | 2659 (97.0) | 2495 (97.0) | 164 (97.0) | 1.000 |
| Antidiabetic agents | 970 (35.4) | 905 (35.2) | 65 (38.5) | 0.390 |
Tyg triglyceride-glucose, CV cardiovascular, TVMI target vessel myocardial infarction, MACCEs, major adverse CV cerebral events, SHR stress-hyperglycemia ratio, BMI body mass index, T2DM type 2 diabetes mellitus, HF heart failure, LVEF left ventricular ejection faction, AMI acute myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, PAD peripheral artery disease, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HbA1c glycosylated hemoglobin A1c FBG fasting blood glucose, hs CRP high-sensitivity C-reactive protein, eGFR estimated glomerular filtration rate, LM left main, DAPT dual antiplatelet therapy